The FDA has approved Emblaveo (Abbvie), an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated intra-abdominal infections (cIAIs) in adults.
STANDARD TREATMENT — Complications of intra-abdominal infections such as cholecystitis and acute perforated appendicitis often include abscess formation and peritonitis. Infections are usually polymicrobial; typical pathogens include enteric gram-negative organisms (most commonly Escherichia coli, Klebsiella...
- A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
- Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
- In Brief: Label Changes for Menopausal Hormone Therapy Products
- In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management
- Denileukin Diftitox (Lymphir) for Cutaneous T-Cell Lymphoma (online only)
- Sevabertinib (Hyrnuo) for NSCLC (online only)
RELEASE
Oral semaglutide 1.5-, 4-, and 9-mg tablets, which were previously approved by the FDA (but never marketed) as the R2 formulation of Rybelsus, have now been approved as Ozempic (see Table 1). Both the original R1 formulation of Rybelsus (3-, 7-, and 14-mg tablets) and the renamed Ozempic tablets are FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at risk for these events.1,2 The R1 (Rybelsus) and R2 (Ozempic) formulations are not interchangeable on a mg-per-mg basis; Ozempic tablets contain inactive ingredients that enhance drug absorption and have greater bioavailability than Rybelsus R1 tablets.
The name change capitalizes on the brand-name recognition of Ozempic, which has been available for subcutaneous administration in …